Replimune: Leerink Analyst Sees Over 80% Price Potential After Quarterly Results
Reading Time: 3 minutes
Replimune undergoes a transformation into a commercial company focused on the oncology product TUDRIQEV. Leerink Partners reiterates its buy recommendation and significantly raises the price target to $31. Better-than-expected quarterly results and solid liquidity secure the financing of the distribution structures. Transformation from developer to commercial provider The Replimune Group (REPL) is advancing the development of cancer treatments as a biotechnology company based on its proprietary RPx platform. The business model focuses...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
